TRICARE R Armed Forces Health Care Program To Provide Access To SBi s STAR trade; Total Ankle Replacement System
Small Bone Innovations, Inc. (SBi) announced today the 9.6 million beneficiaries of the US Department of Defense TRICARE® health care program, which covers armed forces personnel, retirees and their families, will now have access to SBi's STAR™ Total Ankle Replacement system. The STAR is the only total ankle replacement approved through the FDA's rigorous pre-market approval (PMA) process. SBi is a privately-owned orthopedics company focused exclusively on serving patients and their physicians with technologies and treatments for joint replacement (arthroplasty) and post-traumatic reconstruction of the small bones & joints of the thumb, fingers, hand, wrist, elbow, toes, foot & ankle.
CytRx Announces The Presentation Of Bafetinib Study Results At The American Academy For Cancer Research AACR Annual Meeting
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida. Dr. James R. Berenson, Medical & Scientific Director of the Institute for Myeloma & Bone Cancer Research, commented, "As recently reported, our research shows that bafetinib, even in low concentrations, significantly inhibited the cells that cause bone destruction that can lead to devastating consequences in cancer patients such as fractures, bone pain and hypercalcemia.
curasan AG: Novel Bone Regeneration Material Approved For Sale InEurope
curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material. Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation. "With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products", stated Hans Dieter RГ ssler, CEO. Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).
Bariatric Surgery May Lead To Weak Bones Later In Life
Loss of bone minerals during adolescence, when teens should be approaching peak bone mass, could compromise future bone health. A study of 61 teens examined the effect bariatric surgery had on bone mineral content and bone density after surgery. The study, "Bone Loss in Adolescents after Bariatric Surgery, " in the April 2011 issue of Pediatrics (published online March 28), found that bone mineral loss increased with greater changes in weight, accounting for 14 percent of the weight loss. Although bone mineral values declined significantly after surgery, at two years post surgery they were not below the expected values for sex and age. But if the bone loss continues, even at a slow rate, these patients may have an increased risk of fractures later in life.
Unigene s Oral Peptide Drug Delivery Technology Validated With Positive Top-Line Phase 3 Results From Tarsa s ORACAL Trial Of Oral Calcitonin
Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology. The ORACAL study achieved its primary endpoint and the results support Tarsa's plans for a New Drug Application (NDA) submission to the Food and Drug Administration (FDA) targeted before the end of 2011. The study design and endpoints were agreed with the FDA through a formalized Special Protocol Assessment (SPA) process. Tarsa also plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the first half of 2012.
New Data Show Lasting Effects And No Serious Adverse Events With A Percutaneous Decompression Procedure For Lumbar Spinal Stenosis Patients
Patients treated for lumbar spinal stenosis (LSS) with the mild decompression procedure (an alternative to open spinal surgery for many patients), reported sustained improvements in pain and mobility at one year and had no serious adverse events occur, according to the first multi-center one-year post-study follow-up of this patient cohort. Results from this prospective, evidence-based study were presented today at the American Academy of Pain Medicine's 27th Annual Meeting. The post-study results were presented by Timothy R. Deer MD, of The Center for Pain Relief in Charleston, West Virginia. Outcomes of the procedure were assessed one year post treatment for all available patients who had participated in the first mild multi-center U.
Awards Recognize Young Investigators For Their Excellence In Bone And Mineral Research
Dr. Nick Harvey of the MRC Lifecourse Epidemiology Unit, Southampton, UK, and Dr. Michael Hiligsmann of the University of Liege, Liege, Belgium were presented with the ESCEO Young Investigator Awards, supported by a grant from MSD, at a ceremony held during the European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF) now taking place in Valencia, Spain. The Awards, valued at Euro 2, 500, recognize young investigators for their excellence in bone and mineral research and are presented to the lead investigator of the two highest scored abstracts submitted for presentation at the Congress. Dr. Harvey's abstract (OC22) is entitled 'Methylation status of the RXRA promoter in umbilical cord predicts childhood bone mineral content'.
Largest-Ever Biopsy Study In Osteoporosis Demonstrates Superior Bone Forming Activity With Protelos R Strontium Ranelate Versus Bisphosphonates
Protelos® (strontium ranelate) has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented at the European Congress on Osteoporosis and Osteoarthritis (ECCEO011-IOF) in Valencia. (i) Through its unique dual impact on both bone formation and resorption, Protelos substantially reduces fracture risk, the primary goal of osteoporosis treatment. Bone biopsy is the gold standard technique used to examine the effect of osteoporosis treatments on bone. Bone biopsies involve taking a cylindrical sample of real bone from the upper part of the pelvis called the iliac crest.
Springer Editor Honored For His Outstanding Achievements In The Field Of Biosilicate Research
The European Research Council has awarded one of this year's ERC Advanced Grants to Springer editor Dr. Werner Muller, thus supporting his well-established research in the field of biosilicates with prize money of 2.2 million euros. Werner Muller is professor at Mainz University's Institute of Physiological Chemistry. He is a leading expert on the identification, cloning and production of genetically engineered enzymes (silicateins) that allow deep-sea sponges to synthesize their silica skeletons. Professor MГ ller is editor-in-chief of the Springer book series Progress in Molecular and Subcellular Biology and co-editor of the book Inorganic Polyphosphates in this series.
Radical Surgery Removes Half Of Pelvis, Saves Leg
During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient's pelvis. Instead of amputating the connected leg, the surgical team, comprised of orthopaedic, vascular and urologic experts, saved the entire limb. The patient was able to walk with assistance five weeks after surgery. "All I can tell you is that the pain was so bad. I could not walk for one month before my operation, " said Carlos Ortiz, 62, a delivery driver. "Now the pain is gone, simply gone. I am so grateful." Ortiz was diagnosed with a form of cancer called chondrosarcoma, the second most common bone malignancy affecting older adults.
